Fosaprepitant (Emend for Injection (US), Ivemend (EU)) is an antiemetic medication, administered intravenously. It is a prodrug of aprepitant.

Fosaprepitant was developed by Merck & Co. and was approved by the U.S. Food and Drug Administration (FDA) on January 25, 2008, and by the European Medicines Agency (EMA) on January 11 of the same year.